Stock Rating Upgrade
The Value Trend Rating for OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) improved in the last week from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.
Recent Price Action
OncoGenex Pharmaceuticals Inc (NASDAQ: VRSK) stock closed at $241.65 on 3/1/24 after a slight decline of -0.1%. NORMAL trading volume accompanied the decline. The stock has risen 0.7% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
VRSK’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
VERISK ANALYTICS INC has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. VERISK ANALYTICS INC has a slightly negative Appreciation Score of 36 and a neutral Power Rating of 58, with the Low Neutral Value Trend Rating the result.
Be the first to comment